Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SML009
MIFTS: 43

Small Intestine Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Small Intestine Adenocarcinoma

About this section

MalaCards integrated aliases for Small Intestine Adenocarcinoma:

Name: Small Intestine Adenocarcinoma 12 15
Small Intestinal Adenocarcinoma 12 54 17
Adenocarcinoma of the Small Instestine 54 60
Adenocarcinoma of the Small Bowel 54 60
Adenocarcinoma of Small Instestine 54
Adenocarcinoma of Small Intestine 12
Adenocarcinoma of Small Bowel 54
Small Bowel Adenocarcinoma 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:4906
NCIt 51 C7888
ICD10 via Orphanet 35 D01.4
UMLS via Orphanet 75 C0278803
Orphanet 60 ORPHA104075
UMLS 74 C0278803
Sources

Summaries for Small Intestine Adenocarcinoma

About this section
NIH Rare Diseases : 54 Small intestine adenocarcinoma is one type of small bowel cancer, usually occurring in the duodenum or jejunum, that begins in the gland cells. The small intestine is part of the body�??s digestive system, which also includes the esophagus, stomach, and large intestine. The exact cause is still unknown, but it may be due to DNA changes in the small intestine adenocarcinoma cells. The symptoms of small bowel tumors are often vague. The most common symptoms are pain in the belly (which may be the first symptom), weight loss, weakness, fatigue and low red blood cell counts (anemia). The treatment and prognosis for small intestine cancer depends on its stage (tumor size and site) and the presence of metastases. For early stage cancer, surgery may be all that is needed. For more advanced cancer chemotherapy or radiation therapy may be required. Please visit the National Cancer Institute website for additional information:Small Intestine Cancer Treatment (PDQ®)�??Patient Version

MalaCards based summary : Small Intestine Adenocarcinoma, also known as small intestinal adenocarcinoma, is related to lynch syndrome and colorectal adenocarcinoma. An important gene associated with Small Intestine Adenocarcinoma is USP10 (Ubiquitin Specific Peptidase 10), and among its related pathways/superpathways are DNA Damage and Direct p53 effectors. The drugs Oxaliplatin and Cola have been mentioned in the context of this disorder. Affiliated tissues include small intestine, breast and colon.

Disease Ontology : 12 A small intestine carcinoma that derives from epithelial cells of glandular origin.

Sources

Related Diseases for Small Intestine Adenocarcinoma

About this section

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Small Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 29.5 MLH1 MSH2
2 colorectal adenocarcinoma 29.4 MLH1 MSH2
3 adenocarcinoma 10.7
4 celiac disease 1 10.3
5 colorectal cancer 1 10.0 MSH2 MUC6
6 deficiency anemia 10.0
7 iron deficiency anemia 10.0
8 iron metabolism disease 10.0
9 crohn's disease 10.0
10 appendix carcinoid tumor 9.9 MLH1 MSH2
11 colorectal cancer, hereditary nonpolyposis, type 7 9.9 MLH1 MSH2
12 adenosquamous colon carcinoma 9.9 MLH1 MSH2
13 sebaceous adenoma 9.9 MLH1 MSH2
14 lower lip cancer 9.9 MLH1 MSH2
15 polyposis syndrome, hereditary mixed, 1 9.9 MLH1 MUC6
16 anal fistula 9.9 MLH1 MSH2
17 adenomyoma 9.9 MLH1 MUC6
18 melanocytic nevus syndrome, congenital 9.9 MLH1 MSH2
19 childhood kidney cell carcinoma 9.9 MLH1 MSH2
20 colorectal cancer, hereditary nonpolyposis, type 4 9.9 MLH1 MSH2
21 cecum adenocarcinoma 9.9 MLH1 MSH2
22 mucinous adenocarcinoma 9.9
23 gastritis 9.9
24 lymphocytic gastritis 9.9
25 lynch syndrome i 9.9 MLH1 MSH2
26 sebaceous adenocarcinoma 9.9 MLH1 MSH2
27 intestinal benign neoplasm 9.9 MLH1 MSH2
28 muir-torre syndrome 9.9 MLH1 MSH2
29 keratoacanthoma 9.9 MLH1 MSH2
30 colorectal cancer 9.9
31 skin benign neoplasm 9.9 MLH1 MSH2
32 mismatch repair cancer syndrome 9.9 MLH1 MSH2
33 colorectal cancer, hereditary nonpolyposis, type 5 9.8 MLH1 MSH2
34 familial colorectal cancer 9.8 MLH1 MSH2
35 intussusception 9.8
36 aging 9.8
37 dermatofibrosarcoma protuberans 9.8
38 gas gangrene 9.8
39 hemolytic anemia 9.8
40 hereditary hemorrhagic telangiectasia 9.8
41 small intestine lymphoma 9.8
42 lymphoma 9.8
43 acute cystitis 9.8
44 anal canal adenocarcinoma 9.8
45 intestinal obstruction 9.8
46 carcinoid syndrome 9.8
47 hepatoid adenocarcinoma 9.8
48 teratoma 9.8
49 mature teratoma 9.8
50 uterine anomalies 9.8 MLH1 MSH2

Graphical network of the top 20 diseases related to Small Intestine Adenocarcinoma:



Diseases related to Small Intestine Adenocarcinoma
Sources

Symptoms & Phenotypes for Small Intestine Adenocarcinoma

About this section
Sources

Drugs & Therapeutics for Small Intestine Adenocarcinoma

About this section

Drugs for Small Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
2 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
9 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
10 Analgesics Phase 3
11 Adjuvants, Anesthesia Phase 3
12 Anesthetics, General Phase 3
13 Narcotics Phase 3
14 Anesthetics Phase 3
15 Anesthetics, Intravenous Phase 3
16 Central Nervous System Depressants Phase 3
17 Peripheral Nervous System Agents Phase 3
18 Analgesics, Opioid Phase 3
19 Anti-Inflammatory Agents Phase 3
20 HIV Protease Inhibitors Phase 3
21 Serotonin Agents Phase 3
22 Serotonin Antagonists Phase 3
23 Neurotransmitter Agents Phase 3
24 Hormones Phase 3
25
protease inhibitors Phase 3
26 Autonomic Agents Phase 3
27 BB 1101 Phase 3
28 Psychotropic Drugs Phase 3
29 Dermatologic Agents Phase 3,Not Applicable
30 Antipruritics Phase 3
31 Gastrointestinal Agents Phase 3,Phase 2
32 glucocorticoids Phase 3
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
34 Tranquilizing Agents Phase 3
35 Antipsychotic Agents Phase 3
36 Anti-Anxiety Agents Phase 3
37 Antineoplastic Agents, Hormonal Phase 3,Phase 2
38 Hormone Antagonists Phase 3
39 Antiemetics Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
42
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
43
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
44
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
47
Melphalan Approved Phase 2 148-82-3 460612 4053
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Hydroxyurea Approved Phase 2 127-07-1 3657
50
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
5 Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma Not yet recruiting NCT02502370 Phase 3 observation alone;LV5FU2;FOLFOX
6 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
7 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
8 Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
9 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01202409 Phase 2 Panitumumab
10 Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin
11 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
12 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
13 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
14 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
15 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
16 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
17 Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting NCT03108131 Phase 2 Cobimetinib;Atezolizumab
18 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
19 Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT02949219 Phase 2
20 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting NCT02034110 Phase 2 Dabrafenib;Trametinib
21 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
22 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
23 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
24 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
25 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
26 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
27 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
28 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
29 Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer Completed NCT00003439 Phase 1
30 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
31 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
32 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
33 Interleukin-12 in Treating Patients With Cancer in the Abdomen Completed NCT00003046 Phase 1
34 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
35 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1
36 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
37 Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
38 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
39 Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma Recruiting NCT03000179 Phase 1 Avelumab
40 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting NCT03095781 Phase 1 XL888
41 Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease Unknown status NCT03095573 Not Applicable
42 Enteroscopy for Early Diagnosis of Tumors in Celiac Disease Unknown status NCT02325232 Not Applicable
43 Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder Completed NCT00489515
44 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383 Not Applicable
45 Prospective Collection of PillCam SB3 Videos and Raw Data Files With Abnormal Findings for Future Developments (SODA) Recruiting NCT03771508
46 Phenotyping of Small Bowel Adenocarcinoma Active, not recruiting NCT02976090
47 EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer Terminated NCT00087191 Not Applicable EF5;motexafin lutetium

Search NIH Clinical Center for Small Intestine Adenocarcinoma

Sources

Genetic Tests for Small Intestine Adenocarcinoma

About this section
Sources

Anatomical Context for Small Intestine Adenocarcinoma

About this section

MalaCards organs/tissues related to Small Intestine Adenocarcinoma:

42
Small Intestine, Breast, Colon, Endothelial, Pancreas, Appendix
Sources

Publications for Small Intestine Adenocarcinoma

About this section

Articles related to Small Intestine Adenocarcinoma:

(show all 42)
# Title Authors Year
1
Retrospective study of survival time and prognostic factors for dogs with small intestinal adenocarcinoma treated by tumor excision with or without adjuvant chemotherapy. ( 30605388 )
2019
2
Influence of marital status on small intestinal adenocarcinoma survival: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. ( 30532589 )
2018
3
Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. ( 30375264 )
2018
4
DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. ( 30381262 )
2018
5
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? ( 28821192 )
2017
6
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. ( 26892442 )
2016
7
SMALL INTESTINAL ADENOCARCINOMA WITH CARCINOMATOSIS IN A SWIFT FOX (VULPES VELOX). ( 26352968 )
2015
8
Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis. ( 25736860 )
2015
9
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. ( 25710579 )
2015
10
Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. ( 24603585 )
2014
11
Recovering a stuck capsule … and discovering a rare small-intestinal adenocarcinoma. ( 24679662 )
2014
12
Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology. ( 24240591 )
2013
13
Molecular alterations of EGFR in small intestinal adenocarcinoma. ( 23644682 )
2013
14
Small intestinal adenocarcinoma: rarely considered, often missed? ( 23412393 )
2013
15
Epithelial-mesenchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma. ( 24018801 )
2013
16
S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. ( 24062356 )
2013
17
[Expression of Bcl-w protein in human small intestinal adenocarcinoma and effect of Bcl-w siRNA on apoptosis in intestinal adenocarcinoma HuTu-80 cells]. ( 22780970 )
2012
18
Surgical versus non-surgical treatment of feline small intestinal adenocarcinoma and the influence of metastasis on long-term survival in 18 cats (2000-2007). ( 22467965 )
2011
19
Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. ( 22966319 )
2010
20
Small intestinal adenocarcinoma in common marmosets (Callithrix jacchus). ( 20460447 )
2010
21
Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. ( 21088150 )
2010
22
Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. ( 19926579 )
2009
23
Significance of increased apoptosis and Bax expression in human small intestinal adenocarcinoma. ( 19729672 )
2009
24
Small intestine adenocarcinoma in conjunction with multiple adenomas causing acute colic in a horse. ( 18182527 )
2008
25
Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. ( 17951204 )
2007
26
Adjuvant chemotherapy for small intestine adenocarcinoma. ( 17636789 )
2007
27
Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. ( 16501564 )
2006
28
Small intestinal adenocarcinoma in Peutz-Jeghers syndrome. ( 16567896 )
2006
29
Small intestinal adenocarcinoma in Crohn's disease: a case-control study. ( 15058524 )
2004
30
[Crohn's disease and small intestine adenocarcinoma]. ( 11534361 )
2001
31
Caecal adenocarcinoma with multiple synchronous small intestinal adenocarcinoma. ( 9519189 )
1997
32
Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. ( 9052748 )
1997
33
Primary small intestinal adenocarcinoma. ( 9197169 )
1997
34
Survival in small intestinal adenocarcinoma. ( 9014754 )
1996
35
Primary small intestinal adenocarcinoma diagnosed by endoscopic examination prior to operation. ( 2777015 )
1989
36
Small intestinal adenocarcinoma, duodenal carcinoid tumour, and von Recklinghausen's neurofibromatosis. ( 3131195 )
1988
37
Small intestinal adenocarcinoma in cats: 32 cases (1978-1985). ( 3350752 )
1988
38
Activated N-ras oncogene in a transformant derived from a rat small intestinal adenocarcinoma induced by 2-aminodipyrido[1,2-a:3',2'-d]imidazole. ( 3664949 )
1987
39
Small intestinal adenocarcinoma in a horse. ( 3679976 )
1987
40
Small intestinal adenocarcinoma complicating regional enteritis. ( 3965106 )
1985
41
Phenoxy and picolinic acid herbicides and small-intestinal adenocarcinoma in sheep. ( 6150323 )
1984
42
Small-intestinal adenocarcinoma in cattle. ( 16031063 )
1984
Sources

Variations for Small Intestine Adenocarcinoma

About this section

Cosmic variations for Small Intestine Adenocarcinoma:

9 (show top 50) (show all 22375)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM33066 ZZZ3 large intestine,NS,carcinoma,adenocarcinoma c.1366C>T p.P456S 1:77631989-77631989 0
2 COSM6940205 ZRSR2 large intestine,NS,carcinoma,adenocarcinoma c.553G>T p.D185Y 23:15809314-15809314 0
3 COSM4378460 ZRSR2 large intestine,NS,carcinoma,adenocarcinoma c.1385G>A p.R462Q 23:15823178-15823178 0
4 COSM6452015 ZRSR2 large intestine,NS,carcinoma,adenocarcinoma c.917G>A p.R306Q 23:15820296-15820296 0
5 COSM6971229 ZRSR2 small intestine,duodenum,carcinoma,adenocarcinoma c.611G>A p.S204N 23:15815730-15815730 0
6 COSM33067 ZNHIT6 large intestine,NS,carcinoma,adenocarcinoma c.1364T>A p.L455H 1:85657855-85657855 0
7 COSM32824 ZNHIT1 large intestine,NS,carcinoma,adenocarcinoma c.400C>T p.R134W 7:101223799-101223799 0
8 COSM50818 ZNF813 large intestine,NS,carcinoma,adenocarcinoma c.1636G>A p.G546R 19:53491871-53491871 0
9 COSM50466 ZNF536 large intestine,NS,carcinoma,adenocarcinoma c.2533C>G p.L845V 19:30548152-30548152 0
10 COSM50465 ZNF536 large intestine,NS,carcinoma,adenocarcinoma c.1158G>T p.W386C 19:30444720-30444720 0
11 COSM5575790 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 0
12 COSM5576102 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 0
13 COSM50282 ZNF521 large intestine,NS,carcinoma,adenocarcinoma c.799G>C p.E267Q 18:25227119-25227119 0
14 COSM5576231 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 0
15 COSM5575704 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 0
16 COSM50281 ZNF521 large intestine,NS,carcinoma,adenocarcinoma c.3524C>T p.T1175M 18:25224394-25224394 0
17 COSM33404 ZNF385D large intestine,NS,carcinoma,adenocarcinoma c.1161C>G p.H387Q 3:21421241-21421241 0
18 COSM5576098 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 0
19 COSM3732832 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 0
20 COSM50969 ZNF280D large intestine,NS,carcinoma,adenocarcinoma c.2020A>C p.R674R 15:56658461-56658461 0
21 COSM1645478 ZNF276 large intestine,NS,carcinoma,adenocarcinoma c.1373G>A p.C458Y 16:89737999-89737999 0
22 COSM32994 ZNF217 large intestine,NS,carcinoma,adenocarcinoma c.967G>A p.D323N 20:53581860-53581860 0
23 COSM32679 ZNF155 large intestine,NS,carcinoma,adenocarcinoma c.1421A>G p.H474R 19:43997278-43997278 0
24 COSM33366 ZMYM4 large intestine,NS,carcinoma,adenocarcinoma c.4228C>T p.R1410W 1:35415633-35415633 0
25 COSM50671 ZMIZ2 large intestine,NS,carcinoma,adenocarcinoma c.1850G>A p.R617H 7:44763403-44763403 0
26 COSM4762421 ZIC4 stomach,NS,carcinoma,intestinal adenocarcinoma c.305A>C p.N102T 3:147396235-147396235 0
27 COSM3588439 ZIC4 stomach,NS,carcinoma,intestinal adenocarcinoma c.875C>T p.P292L 3:147391060-147391060 0
28 COSM4762419 ZIC4 stomach,NS,carcinoma,intestinal adenocarcinoma c.317A>C p.N106T 3:147396223-147396223 0
29 COSM4762417 ZIC4 stomach,NS,carcinoma,intestinal adenocarcinoma c.401C>T p.A134V 3:147396139-147396139 0
30 COSM50720 ZFPM2 large intestine,NS,carcinoma,adenocarcinoma c.3163G>T p.A1055S 8:105803245-105803245 0
31 COSM304455 ZFHX4 large intestine,NS,carcinoma,adenocarcinoma c.5144A>C p.N1715T 8:76852065-76852065 0
32 COSM50764 ZFHX4 large intestine,NS,carcinoma,adenocarcinoma c.681C>A p.F227L 8:76704769-76704769 0
33 COSM50768 ZFHX4 large intestine,NS,carcinoma,adenocarcinoma c.8291C>T p.P2764L 8:76855212-76855212 0
34 COSM6964399 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.2339C>T p.A780V 16:72957807-72957807 0
35 COSM6974762 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.9467G>A p.S3156N 16:72788809-72788809 0
36 COSM6944275 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.2324C>T p.A775V 16:72957822-72957822 0
37 COSM6946346 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.8875A>G p.K2959E 16:72793807-72793807 0
38 COSM6959905 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.6079G>A p.D2027N 16:72796603-72796603 0
39 COSM6957094 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.3412A>T p.I1138F 16:72889767-72889767 0
40 COSM3512090 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.1670C>T p.S557F 16:72958476-72958476 0
41 COSM278205 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.3623C>T p.S1208L 16:72811945-72811945 0
42 COSM6964818 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 0
43 COSM6961537 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.4043C>T p.P1348L 16:72798639-72798639 0
44 COSM6975522 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.4175C>T p.P1392L 16:72798507-72798507 0
45 COSM6953704 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.1623G>C p.Q541H 16:72958523-72958523 0
46 COSM6975520 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.10851G>A p.W3617* 16:72787425-72787425 0
47 COSM6953000 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 0
48 COSM1233350 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.305C>T p.A102V 16:72959841-72959841 0
49 COSM6845173 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.3863C>T p.T1288M 16:72811578-72811578 0
50 COSM6932345 ZFHX3 large intestine,NS,carcinoma,adenocarcinoma c.2880G>A p.M960I 16:72950805-72950805 0

Copy number variations for Small Intestine Adenocarcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13776 1 1 39600000 Copy number LCK Small bowel adenocarcinoma
2 13777 1 1 39600000 Copy number MDS2 Small bowel adenocarcinoma
3 13778 1 1 39600000 Copy number PAX7 Small bowel adenocarcinoma
4 13779 1 1 39600000 Copy number PRDM16 Small bowel adenocarcinoma
5 13780 1 1 39600000 Copy number RPL22 Small bowel adenocarcinoma
6 13781 1 1 39600000 Copy number SDHB Small bowel adenocarcinoma
7 76578 13 32900000 93800000 Copy number LCP1 Small bowel adenocarcinoma
8 76579 13 32900000 93800000 Copy number LHFP Small bowel adenocarcinoma
9 76580 13 32900000 93800000 Copy number RB1 Small bowel adenocarcinoma
10 106872 17 1 6800000 Copy number USP6 Small bowel adenocarcinoma
11 180663 4 10900000 191273063 Copy number CHIC2 Small bowel adenocarcinoma
12 180664 4 10900000 191273063 Copy number FBXW7 Small bowel adenocarcinoma
13 180665 4 10900000 191273063 Copy number FIP1L1 Small bowel adenocarcinoma
14 180666 4 10900000 191273063 Copy number IL2 Small bowel adenocarcinoma
15 180667 4 10900000 191273063 Copy number KIT Small bowel adenocarcinoma
16 180668 4 10900000 191273063 Copy number PDGFRA Small bowel adenocarcinoma
17 180669 4 10900000 191273063 Copy number PHOX2B Small bowel adenocarcinoma
18 180670 4 10900000 191273063 Copy number RAP1GDS1 Small bowel adenocarcinoma
19 244962 9 1 51800000 Copy number FANCG Small bowel adenocarcinoma
20 244963 9 1 51800000 Copy number JAK2 Small bowel adenocarcinoma
21 244964 9 1 51800000 Copy number MLLT3 Small bowel adenocarcinoma
22 244965 9 1 51800000 Copy number PAX5 Small bowel adenocarcinoma
Sources

Expression for Small Intestine Adenocarcinoma

About this section
Search GEO for disease gene expression data for Small Intestine Adenocarcinoma.
Sources

Pathways for Small Intestine Adenocarcinoma

About this section

Pathways related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
DNA Damage 4
11.6 MLH1 MSH2 USP10
2
Direct p53 effectors 1
11.52 MLH1 MSH2
3
Mismatch repair 1 38 67
Show member pathways
 11.36 MLH1 MSH2
4
Platinum drug resistance 38
11.18 MLH1 MSH2
5
Busulfan Pathway, Pharmacodynamics 62
Show member pathways
 10.9 MLH1 MSH2
6
Doxorubicin Pathway, Pharmacokinetics 62
Show member pathways
 10.76 MLH1 MSH2
7
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 62
10.09 MLH1 MSH2
Sources

GO Terms for Small Intestine Adenocarcinoma

About this section

Cellular components related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.65 MLH1 MSH2 USP10
2 DNA repair GO:0006281 9.63 MLH1 MSH2 USP10
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 MLH1 MSH2
4 mismatch repair GO:0006298 9.4 MLH1 MSH2
5 somatic hypermutation of immunoglobulin genes GO:0016446 9.37 MLH1 MSH2
6 isotype switching GO:0045190 9.32 MLH1 MSH2
7 positive regulation of isotype switching to IgG isotypes GO:0048304 9.26 MLH1 MSH2
8 positive regulation of isotype switching to IgA isotypes GO:0048298 9.16 MLH1 MSH2
9 somatic recombination of immunoglobulin gene segments GO:0016447 8.96 MLH1 MSH2
10 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MLH1 MSH2

Molecular functions related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 single-stranded DNA binding GO:0003697 9.16 MLH1 MSH2
2 mismatched DNA binding GO:0030983 8.96 MLH1 MSH2
3 guanine/thymine mispair binding GO:0032137 8.62 MLH1 MSH2
Sources

Sources for Small Intestine Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....